Details for New Drug Application (NDA): 205641
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in ASMANEX HFA is mometasone furoate. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for 205641
Tradename: | ASMANEX HFA |
Applicant: | Organon |
Ingredient: | mometasone furoate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 205641
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.10MG/INH | ||||
Approval Date: | Apr 25, 2014 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.20MG/INH | ||||
Approval Date: | Apr 25, 2014 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.05MG/INH | ||||
Approval Date: | Aug 12, 2019 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Aug 12, 2022 | ||||||||
Regulatory Exclusivity Use: | NEW STRENGTH |
Expired US Patents for NDA 205641
Complete Access Available with Subscription